74 completed, 18 unknown, 17 recruiting, 15 terminated. 60 Phase 2, 37 Phase 1, 18 Phase 3, 16 Not applicable, 2 Early Phase 1.
Follow Peritoneal Cancer: new trials by email Literature Review of Peritoneal Cancer trials Research Report on Peritoneal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer | Not applicable | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2027-01-01 | 2026-08-05 |
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-10-30 |
| A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 802 | 2026-09-18 | 2026-10-29 |
| Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal Cancer Paricalcitol, pirfenidone - Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma | Phase 2 | Not yet recruiting | Patrick Wagner, MD, FACS | 74 | 2026-09-01 | 2026-10-05 |
| Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma Constitution of a biological collection, Assessment of Quality of Life and level of anxiety/depression - Cancer of the Ovary, Cancer of the Fallopian Tube | Not applicable | Recruiting | Centre Oscar Lambret | 371 | 2025-06-27 | 2026-03-30 |
| Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors vvDD-hIL-2-RG-1 - Gastric Neoplasms, Esophageal Cancer | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 18 | 2025-05-06 | 2025-06-03 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer Fluzoparib, Bevacizumab, Paclitaxel - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 105 | 2024-11-27 | 2024-12-16 |
| Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test Ovarian Cancer, Fallopian Tube Cancer | Unknown | Uppsala University Hospital | 125 | 2024-05-30 | 2024-06-06 | |
| Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer KELIM, Carboplatin plus Paclitaxel, Interval debulking surgery - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | The University of Hong Kong | 18 | 2024-05-28 | 2025-07-02 |
| The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study. scan - Peritoneal Cancer, Peritoneal Metastases | Completed | Odense University Hospital | 34 | 2024-03-15 | 2026-03-16 | |
| Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery Acute Normovolemic Hemodilution/ANH - Ovarian Cancer, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 86 | 2024-02-23 | 2026-04-01 |
| Nudge to Gynecologic Oncology Nudge - Ovarian Cancer, Fallopian Tube Cancer | Not applicable | Active not recruiting | Abramson Cancer Center at Penn Medicine | 20 | 2024-01-19 | 2025-09-19 |
| An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib Mirvetuximab Soravtansine-gynx, Olaparib - Ovary Cancer, Peritoneal Cancer | Phase 2 | Recruiting | University of Colorado, Denver | 53 | 2023-10-03 | 2026-07-13 |
| MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer MIRRORS Protocol, Standard Open Cytoreductive Surgery - Ovarian Cancer, Ovarian Neoplasm | Not applicable | Unknown | Royal Surrey County Hospital NHS Foundation Trust | 20 | 2023-10-02 | 2023-11-18 |
| Choices About Genetic Testing And Learning Your Risk With Smart Technology Relational Agent (RA), Enhanced Usual Care (EUC) - Ovarian Cancer, Fallopian Tube Cancer | Not applicable | Completed | Rutgers, The State University of New Jersey | 50 | 2023-09-26 | 2026-03-06 |
| Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer Carboplatin - Ovarian Cancer, Relapsed Ovarian Cancer | Phase 2 | Recruiting | University College, London | 80 | 2023-05-24 | 2024-04-12 |
| Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer Huaier granule - Primary Ovarian Cancer, Fallopian Tube Cancer | Not applicable | Unknown | Ruijin Hospital | 30 | 2023-05-01 | 2023-03-31 |
| MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer FT538, Enoblituzumab - Cancer, Solid Tumor | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 1 | 2023-04-28 | 2025-08-14 |
| A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer KAND567, Carboplatin - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Completed | Novakand Pharma AB | 18 | 2023-04-26 | 2025-06-08 |
Showing 20 of 143. Sign in to see all of them.
Fallopian Tube Neoplasms (113) · Ovarian Neoplasms (106) · Carcinoma, Ovarian Epithelial (28) · Endometrial Neoplasms (15) · Neoplasms (15) · Recurrence (10) · Uterine Cervical Neoplasms (9) · Breast Neoplasms (6) · Colorectal Neoplasms (6) · Pancreatic Neoplasms (6) · Peritoneal Neoplasms (6) · Stomach Neoplasms (6) · Esophageal Neoplasms (4) · Liver Neoplasms (4) · Neoplasm Metastasis (4)
Neoplasms by Site (133) · Adnexal Diseases (123) · Endocrine Gland Neoplasms (123) · Endocrine System Diseases (123) · Female Urogenital Diseases (123) · Female Urogenital Diseases and Pregnancy Complications (123) · Genital Diseases (123) · Genital Diseases, Female (123) · Urogenital Diseases (123) · Urogenital Neoplasms (123) · Genital Neoplasms, Female (122) · Gonadal Disorders (121) · Neoplasms (121) · Ovarian Diseases (118) · Fallopian Tube Diseases (112)
Carboplatin (22) · Paclitaxel (20) · Bevacizumab (15) · Gemcitabine (9) · mirvetuximab soravtansine (6) · rucaparib (6) · liposomal doxorubicin (5) · niraparib (5) · pembrolizumab (5) · Cisplatin (4) · Cyclophosphamide (4) · Hyperthermic Intraperitoneal Chemotherapy (4) · Pemetrexed (4) · Surveys and Questionnaires (4) · Nivolumab (3)
Memorial Sloan Kettering Cancer Center (10) · Dana-Farber Cancer Institute (8) · M.D. Anderson Cancer Center (7) · pharmaand GmbH (5) · AA Secord (3) · AbbVie (3) · Abramson Cancer Center at Penn Medicine (3) · University College, London (3) · AGO Study Group (2) · CanariaBio Inc. (2) · Duke University (2) · Eli Lilly and Company (2) · Genentech, Inc. (2) · GlaxoSmithKline (2) · H. Lee Moffitt Cancer Center and Research Institute (2)
United States (100) · United Kingdom (16) · Canada (15) · Spain (13) · Italy (11) · Australia (10) · Israel (10) · Belgium (9) · South Korea (9) · Germany (8) · France (7) · China (5) · Czechia (5) · Denmark (5) · Netherlands (5)
Ursula Matulonis, MD (5) · Angeles A Secord, MD (4) · Dennis Chi, MD (3) · Paul Sabbatini, MD (2) · Simon Butler-Manuel, MD (2) · Sunil Gupta, MD, FRCPC (2) · Susana M. Campos, MD (2) · Agnieszka Michael, MBBS, PhD (1) · Alexander B Olawaiye, MD (1) · Alexandra R Brandt-Kerkhof, MD (1) · Alvaro Arjona Sanchez, MD (1) · Amit Oza (1) · Amit Oza, M.D. (1) · Andreas Obermair, MD FRANZCOG CGO (1)
PMID 35397664, PMID 37185961, PMID 31685558, PMID 35170751, PMID 17161453, PMID 17708508, PMID 18829088, PMID 19264351, PMID 19819917, PMID 21815133, PMID 22487536, PMID 22542580, PMID 23142076, PMID 23994535, PMID 25827292, PMID 26119093, PMID 26405584, PMID 26669784, PMID 27908594, PMID 27998236, PMID 28916367, PMID 29799676, PMID 30347019, PMID 30954352, PMID 31023318, PMID 31076365, PMID 31142357, PMID 31194225, PMID 31194228, PMID 32193378, PMID 32247603, PMID 32359490, PMID 32375688, PMID 32771276, PMID 32861537, PMID 33030975, PMID 33119478, PMID 33528867, PMID 33941784, PMID 34009291, PMID 34019431, PMID 35298906, PMID 35779095, PMID 36410913, PMID 36482193, PMID 36633893, PMID 36716407, PMID 37212825, PMID 37262961, PMID 37935524
2016 (2), 2019 (2), 2025 (2), 2009 (1), 2015 (1), 2018 (1), K07CA093512 (1), K07CA204380 (1), K12HD043446 (1), P01CA111412 (1), R01CA252211 (1), R21CA216796 (1)